Table 4.

In vitro susceptibilities of blood stream infection isolates of Candida spp. to fluconazole and investigational antifungal agents (SENTRY Program, 1997 to 1999)

Species (no. tested)Antifungal agentMIC (μg/ml) and % susceptible by year
199719981999
50/90%% Sa50/90%% Sa50/90%% Sa
C. albicans(658)Fluconazole0.25/0.5990.25/0.5980.25/0.25100
Ravuconazole0.007/0.03990.007/0.03990.007/0.015100
Voriconazole0.015/0.06980.007/0.03990.007/0.015100
C. glabrata(180)Fluconazoleb 16/32488/16634/1683
Ravuconazole0.25/1920.25/1950.12/194
Voriconazole0.25/1910.25/1950.12/0.596
C. parapsilosis(179)Fluconazole0.5/21000.5/1980.5/1100
Ravuconazole0.015/0.061000.015/0.061000.015/0.06100
Voriconazole0.03/0.121000.015/0.061000.015/0.03100
C. tropicalis(104)Fluconazole1/21000.5/11000.5/297
Ravuconazole0.03/0.121000.03/0.121000.015/0.1297
Voriconazole0.06/0.121000.03/0.121000.03/0.1297
C. krusei(20)Fluconazole32/—c 032/—016/—0
Ravuconazole0.25/—1000.25/—1000.25/—100
Voriconazole0.5/—1000.25/—1000.25/—100
  • a % S, percent susceptible at a MIC of ≤8 μg/ml (fluconazole) or ≤1 μg/ml (all other agents).

  • b P = 0.0004 for trend in susceptibility by year.

  • c —, MIC90 not calculated because <10 isolates were identified during the year.